PATENT CLAIM ANALYSIS

Application Number: 16135096
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["702", "019000"]

Abstract:
The disclosure relates to methods and assay that assists in the diagnosis of autoimmune and chronic inflammatory disorders such as systemic lupus erythematosus and rheumatoid arthritis by analyzing drug-responsiveness of an interferon signal in a hematological sample (e.g., blood) obtained from a human subject. The assay involves comparing the interferon signal in a control aliquot of the sample with the same interferon sample in an aliquot that has been exposed to a therapeutic modality (e.g., combined with a drug) that is known to be efficacious to treat the disorder. A significant difference between the interferon signals of the control and treated aliquots that corresponds to a characteristic interferon signature for the disorder indicates that the subject is afflicted with, or is likely to develop, the disorder.

Claim (Index 5):
The method of  claim 2 , wherein the ACID is PA and the drug is selected from the group consisting of corticosteroids, non-steroidal anti-inflammatory drugs, tumor necrosis factor alpha inhibitors, immune suppressants, anti-rheumatics, and combinations of these.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 97.0
- Lexical Diversity: 1.75641
- Patent Class: 702.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13252335', '14745939', '13211092', '14122611', '14902409']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.2355089369827255
- 35 USC 102 Novelty (BERT): 0.4901628564997203
- Combined Prediction Score: 0.260974328934425
- Mean Citation Score: 202.817904
- Max Citation Score: 207.33003
- Similarity Product: 137.88475611570058

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test